Company Analysis Shandong Weigao Group Medical Polymer Company Limited
1. Summary
Advantages
- The stock's return over the last year (35.48%) is higher than the sector average (23.98%).
- Current debt level 11.52% is below 100% and has decreased over 5 years from 20.87%.
- The company's current efficiency (ROE=8.95%) is higher than the sector average (ROE=3.98%)
Disadvantages
- Price (6.11 HK$) is higher than fair price (5.32 HK$)
- Dividends (3.45%) are below the sector average (4.32%).
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
Shandong Weigao Group Medical Polymer Company Limited | Healthcare | Index | |
---|---|---|---|
7 days | 0% | -10.3% | 3.3% |
90 days | 7% | 0.3% | 16% |
1 year | 35.5% | 24% | 42.5% |
1066 vs Sector: Shandong Weigao Group Medical Polymer Company Limited has outperformed the "Healthcare" sector by 11.49% over the past year.
1066 vs Market: Shandong Weigao Group Medical Polymer Company Limited has significantly underperformed the market by -7.05% over the past year.
Stable price: 1066 is not significantly more volatile than the rest of the market on "Hong Kong Exchanges" over the last 3 months, with typical variations of +/- 5% per week.
Long period: 1066 with weekly volatility of 0.6822% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (6.11 HK$) is higher than the fair price (5.32 HK$).
Price is higher than fair: The current price (6.11 HK$) is 12.9% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (9.49) is lower than that of the sector as a whole (37.2).
P/E vs Market: The company's P/E (9.49) is lower than that of the market as a whole (43.79).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (0.7741) is lower than that of the sector as a whole (1.93).
P/BV vs Market: The company's P/BV (0.7741) is lower than that of the market as a whole (1.59).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (1.5) is lower than that of the sector as a whole (4.03).
P/S vs Market: The company's P/S indicator (1.5) is lower than that of the market as a whole (2.5).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (8.13) is higher than that of the sector as a whole (2.91).
EV/Ebitda vs Market: The company's EV/Ebitda (8.13) is lower than that of the market as a whole (9.93).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 0.3599% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (0.3599%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (0%).
5.4. ROE
ROE vs Sector: The company's ROE (8.95%) is higher than that of the sector as a whole (3.98%).
ROE vs Market: The company's ROE (8.95%) is higher than that of the market as a whole (2.89%).
5.5. ROA
ROA vs Sector: The company's ROA (6.04%) is higher than that of the sector as a whole (2.89%).
ROA vs Market: The company's ROA (6.04%) is higher than that of the market as a whole (3.12%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (0%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (20.88%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 3.45% is below the average for the sector '4.32%.
7.2. Stability and increase in payments
Dividend stability: The company's dividend yield 3.45% has been steadily paid over the past 7 years, DSI=0.79.
Weak dividend growth: The company's dividend yield 3.45% has been growing weakly or stagnant over the past 5 years. Growth over only 1 year.
7.3. Payout percentage
Dividend Coverage: Current payments from income (42.13%) are at a comfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription